Charles River Laboratories | CRL - Gross Profit On Sales


Charles River Laboratories reported $279.32M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Agilent USD 990M 44M Mar/2026
Align Technology USD 736.59M 53M Mar/2026
Bio-Rad Laboratories USD 345.2M 1.8M Dec/2025
Bruker USD 379.8M 69.4M Mar/2026
Cardinal Health USD 2.5B 101M Mar/2026
Charles River Laboratories USD 279.32M 7.36M Mar/2026
Cigna USD 6.08B 50.37B Mar/2026
Concord Medical Services Hldg CNY -37.42M 26.25M Jun/2023
CVS Health USD 15.62B 2.06B Mar/2026
Danaher USD 3.59B 375M Mar/2026
Dentsply International USD 427M 16M Mar/2026
Elevance Health USD 11.68B 889M Dec/2025
Humana USD 4.82B 754M Jun/2025
Illumina USD 721M 38M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Intrexon USD -297K 167K Jun/2024
IQVIA Holdings USD 1.07B 52M Mar/2026
Laboratory Of America USD 1.01B 20.6M Mar/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
McKesson USD 3.68B 143M Dec/2025
Merck EUR 3.07B 104M Mar/2026
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Quest Diagnostics USD 906M 33M Mar/2026
Revvity USD 387.66M 34M Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
UnitedHealth USD 18.49B 2.14B Dec/2025
Veradigm USD 83.44M 3.95M Sep/2022
Waters USD 542M 15.42M Mar/2026
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026